Cancers are comprised of heterogeneous subpopulations with various tumor-initiating capacities， yet key stem cell genes associated with enhanced tumor initiating capacities and their regulatory mechanisms remain elusive. Here we analyzed patient-derived xenografts from melanoma， colon， and pancreatic cancer tissues and identified enrichment of tumor-initiating cells in MHC class I-hi cells， where CDK1， a master regulator of the cell cycle， was upregulated. Overexpression of CDK1， but not its kinase-dead variant， in melanoma cells increased their spheroid forming ability， tumorigenic potential， and tumor-initiating capacity; inhibition of CDK1 with pharmacological agents reduced these charact... More
Cancers are comprised of heterogeneous subpopulations with various tumor-initiating capacities， yet key stem cell genes associated with enhanced tumor initiating capacities and their regulatory mechanisms remain elusive. Here we analyzed patient-derived xenografts from melanoma， colon， and pancreatic cancer tissues and identified enrichment of tumor-initiating cells in MHC class I-hi cells， where CDK1， a master regulator of the cell cycle， was upregulated. Overexpression of CDK1， but not its kinase-dead variant， in melanoma cells increased their spheroid forming ability， tumorigenic potential， and tumor-initiating capacity; inhibition of CDK1 with pharmacological agents reduced these characteristics， which was unexplained by the role of CDK1 in regulating the cell cycle. Proteomic analysis revealed an interaction between CDK1 and the pluripotent stem cell transcription factor Sox2. Blockade or knockdown of CDK1 resulted in reduced phosphorylation， nuclear localization， and transcriptional activity of Sox2. Knockout of Sox2 in CDK1-overexpressing cells reduced CDK1-driven tumor-initiating capacity substantially. Furthermore， GSEA analysis of CDK1-hi tumor cells identified a pathway signature common in all three cancer types， including E2F， G2M， MYC， and spermatogenesis， confirming a stem-like nature of CDK1-hi tumor cells. These findings reveal a previously unrecognized role for CDK1 in regulating tumor-initiating capacity in melanoma and suggest a novel treatment strategy in cancer via interruption of CDK1 function and its protein-protein interactions.
